Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future
American Journal of Cardiovascular Drugs · 2025-05 · 25 (3) · 293-306
DOI: 10.1007/s40256-024-00712-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 20.12.2024. Verfasst von Taha Mansoor und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Dr, Kalamazoo, MI, USA. taha.mansoor…. Hauptthemen laut MEDLINE: RNA, Small Interfering, PCSK9 Inhibitors, Proprotein Convertase 9, Anticholesteremic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Reducing low-density lipoprotein cholesterol (LDL-C) levels has been shown to reduce the risk of developing atherosclerotic cardiovascular disease (ASCVD). Statins are the foundation of LDL-C lowering therapy with other non-statin agents used in circumstances where goal LDL-C levels are not reached or owing to intolerance to adverse effects of statins. In 2003, the discovery of the role of the proprotein convertase subtilisin/kexin type 9 (PCSK9) system in promoting elevated LDL-C levels led to new avenues of drug development to achieve target LDL-C. In 2021, inclisiran, a small interfering ribonucleic acid (siRNA) molecule targeting PCSK9 was approved by the Food and Drug Administration (FDA). Inclisiran has demonstrated effective reductions of LDL-C, such as in the large phase-3 ORION-9, ORION-10, and ORION-11 trials in which it achieved LDL-C reductions of 39.7%, 52.3%, and 49.9%, respectively. This review discusses the current clinical evidence and ongoing clinical studies of inclisiran as well as analyzes other areas of PCSK9 inhibition development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Dr, Kalamazoo, MI, USA. taha.mansoor@wmed.edu.
- Shifa College of Medicine, Islamabad, Pakistan.
- Department of Cardiology, Henry Ford Hospital, Detroit, MI, USA.
- Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA, USA.
- Division of Cardiology, Virginia Commonwealth University, Richmond, VA, USA.
- Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Zitieren
APA
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., & Koshy, S. K. G. (2025). Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. American Journal of Cardiovascular Drugs, 25(3), 293-306. https://doi.org/10.1007/s40256-024-00712-x
Vancouver
Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, et al. Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. American Journal of Cardiovascular Drugs. 2025;25(3):293-306. doi:10.1007/s40256-024-00712-x
BibTeX
@article{Mansoor2025,
author = {Mansoor, Taha and Rao, Bassam Hamid and Gupta, Kartik and Parikh, Sachin S and Abramov, Dmitry and Mehta, Anurag and Al Rifai, Mahmoud and Virani, Salim S and Nambi, Vijay and Minhas, Abdul Mannan Khan and Koshy, Santhosh K G},
title = {Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future},
journal = {American Journal of Cardiovascular Drugs},
year = {2025},
volume = {25},
number = {3},
pages = {293--306},
doi = {10.1007/s40256-024-00712-x}
}
EUVIMED